JIMT-1 Cells

Name: CLS Cell Lines Service GmbH
Address: Dr.-Eckener-Straße 8, Eppelheim, 69214, DE
Telephone: +496221405780
Price range: €€€

USUSD$395.00*

Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 10⁶ cells for adherent lines or 5 × 10⁶ cells for suspension lines (refer to the batch CoA for details).

價格不含稅，另加運費

cryovial

產品編號： 305433

安全資料表

產品說明書

分析證明書 (CoA)

說明	The JIMT-1 cell line is derived from a HER2-positive human breast carcinoma and is known for its resistance to trastuzumab, a commonly used HER2-targeted therapy. This makes JIMT-1 a valuable model for studying mechanisms of resistance to anti-HER2 treatments and for developing new therapeutic strategies. Unlike many other HER2-positive breast cancer cell lines, JIMT-1 mimics clinical cases where initial responses to HER2-targeted therapies are observed, but resistance subsequently develops. This feature has made it instrumental in exploring the efficacy of new drugs and combination therapies aimed at overcoming trastuzumab resistance. JIMT-1 cells are also employed in studies investigating the interplay between HER2 and other signaling pathways, such as those involving the epidermal growth factor receptor (EGFR). Cross-talk between these pathways contributes to the cells' resistance to conventional therapies. Research has shown that JIMT-1 cells respond variably to different tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs). For example, while the cell line exhibits resistance to trastuzumab-emtansine (T-DM1) and shows only partial sensitivity to newer agents like trastuzumab-deruxtecan (T-DXd), it has been demonstrated that alternative ADCs such as disitamab vedotin (DV) might offer enhanced efficacy. In vitro studies highlight the versatility of JIMT-1 for screening drugs that target not only HER2 but also other molecular pathways. These studies provide critical data for evaluating the synergistic effects of combination treatments involving ADCs and TKIs or novel targeted therapies. The cell line's behavior in various drug resistance scenarios underscores its importance in preclinical drug development, particularly for HER2-positive breast cancer with acquired or intrinsic resistance.
生物體	Human
組織	Breast
疾病	Breast ductal carcinoma
轉移部位	Pleural effusion
同義詞	JIMT1, JIMT

年齡	62 years
性別	Female
族裔	Caucasian
形態學	Epithelial-like
生長特性	Adherent, monolayer

引用	JIMT-1 (Cytion catalog number 305433)
生物安全等級	1
NCBI_TaxID	9606
Cellosaurus 編號	CVCL_2077

致癌基因	HER-2 (insensitive to HER-2-inhibiting drugs, e.g. trastuzumab), ER-, PR-, AR-
突變譜	Mutation: PIK3CA, p.Cys420Arg (c.1258T>C), heterozygous; Mutation: TP53, p.Arg248Trp (c.742C>T), homozygous

培養基	DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a)
營養補充品	Supplement the medium with 10% heat-inactivated FBS
解離試劑	Accutase
傳代培養	Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
播種密度	1 x 10⁴ cells/cm²
冷凍培養基	As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
細胞解凍與培養	Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.
培養環境	37°C, 5% CO₂, humidified atmosphere.
運送條款	Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.
儲存條件	For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

不孕症	Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

批次編號	證書類型	日期	型號
305433-190525	分析證明書	21. Jul. 2025	305433

JIMT-1 Cells

一般資訊

特徵

監管數據

生物分子資料

處理方式

品質控制與分子分析

分析證明書 (CoA)